BACK

Bladder Trials

Clinical trial information


Select trial for more information

Area under investigation=true,Metastatic urothelial carcinoma,Muscle Invasive Urothelial Carcinoma

DESTINY-PanTumor02 trial overview

Tumor

Early-stage NSCLC adenocarcinoma following complete surgical resection (R0) that is ctDNA-positive or has high-risk pathological features

Trial Identifier

NCT06564844

Phase

III

Stage

Treatment-naïve Stage I

Regimen

Dato-DXd + rilvegostomig; rilvegostomig; SoC; abc

Visit ct.gov

fam-trastuzumab deruxtecan-nxki in US only; trastuzumab deruxtecan in other regions of the world.

Go

TROPION-Urothelial04 trial overview

Tumor

High-risk muscle invasive urothelial carcinoma

Trial Identifier

NCT07720284

Phase

III

Regimen

Dato-DXd + rilvegostomig; Dato-DXd; nivolumab or durvalumab or EV + pembrolizumab

Visit ct.gov
Go

TROPION-PanTumor03 trial overview

Tumor

Advanced solid tumors (endometrial, gastric, mCRPC, ovarian, colorectal, metastatic urothelial carcinoma, BTCs)

Trial Identifier

NCT05489211

Phase

II

Regimen

Dato-DXd; Dato-DXd + capecitabine or 5-FU; Dato-DXd + prednisone or prednisolone; Dato-DXd + carboplatin + bevacizumab followed by Dato-DXd + bevacizumab; Dato-DXd + bevacizumab + (5-FU + leucovorin or capecitabine); Dato-DXd+ 5-FU/leucovorin or capecitabine + bevacizumab; Dato-DXd + rilvegostomig or carboplatin/cisplatin

Visit ct.gov
Go

Some compounds herein refer to selected AstraZeneca pipeline products still under development. AstraZeneca pipeline products are investigational products and, as such, are not approved by the US Food & Drug Administration (FDA), the European Medicines Agency (EMA) or any other regulatory agency for the uses under investigation. Information regarding these investigational products should, under no circumstances, be regarded as a recommendation for their use or of their safety or efficacy.

This site is intended for US Healthcare Professionals.

Veeva ID: Z4-84958 US-109129 DE-92568 Last Updated October 20263/26
©2026 AstraZeneca. All rights reserved.